The primary mechanisms we see cited in the literature include: VEGF upregulation: BPC-157 increases vascular endothelial growth factor, which drives new capillary formation in injured tissue
Specifically: *T-cell differentiation: Adequate intracellular glutathione promotes the differentiation of nave T-cells toward regulatory T-cells (Tregs) rather than pro-inflammatory Th1 and Th17 cells
Yes, but in small, mostly Russian-language reports
However, advances in ADC technology and growing clinical demands have broadened its scope beyond cancer
This could give it broader therapeutic potential for: As of 2025, Dihexa has not yet entered large-scale, double-blind, placebo-controlled clinical trials for widespread human use
Glutathione works by reducing melanin formation and detoxifying the body a natural process that takes time